Mobile

A phase II, open-label, prospective, multicenter study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) study in patients with follicular grade I...

Mise à jour : Il y a 5 ans
Référence : EUCTR2006-004850-26

A phase II, open-label, prospective, multicenter study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) study in patients with follicular grade I-II lymphoma after 4 cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) therapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The objectives of this study are to evaluate the efficacy and safety of the Zevalin study regimen after 4 cycles of FMR.

Critère d'inclusion

  • follicular grade I-II ,LYMPHOMA

Liens